Ebola Vaccines Elicit Immune Responses in Liberian Adults — Physician’s First Watch
Ebola Vaccines Elicit Immune Responses in Liberian Adults
By Amy Orciari Herman
Two investigational vaccines against Ebola virus safely provoked immune responses in a large group of Liberian adults, according to an industry-supported, phase 2 trial in the New England Journal of Medicine.
Some 1500 nonpregnant adults without a history of Ebola disease were randomized to receive injections of the chimpanzee adenovirus 3–based vaccine (ChAd3-EBO-Z), the recombinant vesicular stomatitis virus–based vaccine (rVSVΔG-ZEBOV-GP), or matching placebo. By 1 month, an antibody response was observed in 71%–84% of active-vaccine recipients, versus 3% of placebo recipients. Antibody responses were largely maintained at 1 year.
Serious adverse events did not differ across the groups.
Dr. Carlos del Rio of NEJM Journal Watch Infectious Diseases commented, "These findings suggest that we have potentially two highly immunogenic Ebola vaccines that could be deployed when the next outbreak occurs."